Thursday - May 15, 2025
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Barclays Global Healthcare Conference on Thursday, March 16, 2023 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time).
There will be simultaneous and archived webcasts available at https://event.webcasts.com/event_security_fail.html
and www.radnet.com under the “About RadNet'' menu section and “News and Press Releases'' sub-menu of the website.
Details for RadNet's Presentation: | |||
Date: | Thursday, March 16, 2023 | ||
Time: | 9:30 a.m. Eastern Time / 6:30 a.m. Pacific Time | ||
Location: | Loews Miami Beach Hotel | ||
URL: https://event.webcasts.com/event_security_fail.html |
About RadNet, Inc.
RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 357 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,000 employees. For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928
Last Trade: | US$59.25 |
Daily Change: | -1.10 -1.82 |
Daily Volume: | 258,465 |
Market Cap: | US$4.390B |
April 15, 2025 March 13, 2025 February 27, 2025 February 26, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load